Picture of Indivior logo

INDV Indivior Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareAdventurousMid CapSucker Stock

Momentum

Relative Strength (%)
1m+0.41%
3m-23.19%
6m+5.48%
1yr-33.58%
Volume Change (%)
10d/3m+103.49%
Price vs... (%)
52w High-32.15%
50d MA-6.39%
200d MA-10.25%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)7.2
PEG Ratio (f)1.76
EPS Growth (f)4.26%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value223.09
Price to Tang. Bookn/a
Price to Free Cashflown/a
Price to Sales1.98
EV to EBITDA70.32

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital0.68%
Return on Equity12.2%
Operating Margin0.36%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue$m7856477919011,0931,270.681,409.011.69%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-57.26-5.69+67.67+38.35+6.31-12.46+25.22n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Indivior EPS forecast chart

Profile Summary

Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.

Directors

Last Annual
December 31st, 2023
Last Interim
March 31st, 2024
Incorporated
September 26th, 2014
Public Since
December 23rd, 2014
No. of Shareholders
806
No. of Employees
1,051
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
134,125,403

INDV Share Price Performance

Upcoming Events for INDV

Half Year 2024 Indivior PLC Earnings Release

Similar to INDV

Picture of Alliance Pharma logo

Alliance Pharma

gb flag iconLondon Stock Exchange

Picture of Animalcare logo

Animalcare

gb flag iconLondon Stock Exchange

Picture of Argent BioPharma logo

Argent BioPharma

gb flag iconLondon Stock Exchange

Picture of AstraZeneca logo

AstraZeneca

gb flag iconLondon Stock Exchange

Picture of Beximco Pharmaceuticals logo

Beximco Pharmaceuticals

gb flag iconLondon Stock Exchange

FAQ